WHO has made a written statement regarding the use of the Covovax (NVX-CoV2373) vaccine produced by the Indian Serum Institute under license from the US pharmaceutical company Novavax.
It was stated in the statement that the emergency use of Covovax was approved, and it was emphasized that the decision would greatly support the ongoing efforts to vaccinate more people in low-income countries.
WHO Deputy Director-General Dr Mariangela Simao used the phrase. “Even as new variants emerge, vaccines remain one of the most effective tools to prevent people from serious illness and death from Covid-19.”
With this decision, WHO has approved the 9th Covid-19 vaccine for emergency use.
WHO first gave the Covid-19 vaccine produced by Pfizer-BioNTech on December 31, 2020, then Oxford-AstraZeneca, the vaccine produced by the Indian Serum Institute (SII), AstraZeneca’s vaccine manufacturer, Moderna, Janssen and China. It gave emergency use approval to the vaccines produced by the Sinopharm company.
The organization had approved the emergency use of the new Sinovac vaccine developed by China, which was also used in Turkey on June 1, 2021, and the Covaxin vaccine produced in India on November 3, 2021.